Boundless Bio is thrilled to announce a significant funding milestone, having successfully raised $72.5 million in its latest financing round. This infusion of capital will accelerate our mission to discover and develop groundbreaking cancer therapeutics that target the increasingly recognized role of extrachromosomal DNA (ecDNA) in tumorigenesis, treatment resistance, and recurrence. Understanding that cancer cells can free themselves from conventional DNA limitations, leading to the uncontrolled proliferation of oncogenes, Boundless Bio is at the forefront of innovative strategies designed to dismantle these survival mechanisms. With this funding, we will expand our research capabilities, drive the development of novel therapeutics, and navigate the path toward more effective cancer treatments. Our dedicated team is fueled by an unwavering commitment to tackling the hardest-to-treat cancers, and our collaborative spirit forms the bedrock of our success. Every member of the Boundless Bio family plays a critical role in pushing the boundaries of science. This financial boost not only signifies the trust our investors place in our vision but also enhances our capacity to offer meaningful career opportunities and foster personal growth within a vibrant, purpose-driven culture. As we continue our fight against cancer, we remain inspired by the patients who depend on our success and are unwavering in our commitment to transforming lives through cutting-edge research. At Boundless Bio, we are all in—unbound by convention, and bound to save lives.










.png&w=3840&q=75)


